Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease
about
MAO-inhibitors in Parkinson's DiseaseInduction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.Zydis selegiline in the management of Parkinson's disease.Pharmacotherapy for Parkinson's disease.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's DiseaseSafety of rasagiline for the treatment of Parkinson's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Adjunctive therapy in Parkinson's disease: the role of rasagiline.Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Transition metal-free decarboxylative alkylation reactions.Rasagiline in treatment of Parkinson's disease.Role of rasagiline in treating Parkinson's disease: Effect on disease progression.Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case reportClinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.Client perception of therapeutic factors in group psychotherapy and growth groups: an empirically-based hierarchical model.Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic CPharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.
P2860
Q24629770-1BB088C9-DE06-4784-9B90-2E7C2FF07234Q34725080-63234741-9F2F-4847-AD32-33F24AECC462Q35625767-7BB14DFB-6F89-4CB2-B15D-62B3B5340E7CQ36054372-8B352F59-96E9-478E-BFC8-68453923EA89Q36177001-A181D605-6C5C-48FF-A611-EAE0A46821BBQ36968199-ED9C86AD-2C14-482E-BDC6-5BB871F5775DQ37016031-B3811023-E9FE-4839-91F9-DFF73A773026Q37016034-AD3902D9-9985-466A-B39C-D90A2C289827Q37211800-FDE9B624-35A8-4271-AC0E-AA61B06253B5Q37859776-AAAE32D1-F2DC-4A65-9C28-D06AEC521EAAQ37963572-6571938E-3CA5-44B7-8E6A-37616BA15532Q38026830-40CE448C-6936-4228-8FC2-FD686545F87AQ38134903-F5CC703D-5AF8-4FC9-9D17-4518A56FD947Q38242390-8659C49E-E46F-4C30-9FE2-5F12B982C0A7Q38246682-8CCB5917-B859-4101-9BF2-E39FE42BEA6EQ38260834-89D463A7-988F-4E9A-8034-3C3064D0CF9FQ38865983-9C6BEA7F-5C6B-4374-867F-637F25DCF23BQ38996629-547897BD-69FB-4856-BECD-4D5974F40C76Q39315311-10F08E7E-01F3-4334-85D9-6C995956C6E6Q41527937-AFDC5567-F45B-4517-9F8B-81514FAD41B2Q42112507-D52174CB-789E-42CE-8CDE-78E199F1B5D0Q43073052-FD211542-421C-4BEA-AF19-ECB99B63E54CQ43076967-E3820EA2-60FE-4FE8-932A-00FFC585E2B4Q43521319-DEE59CDF-A41A-4BD2-8BA7-CC14E4A7F6F0Q46654865-D3E88FC2-02D1-4E4E-82B6-E3792FF238E5Q47795479-C0BFFC46-A382-4629-8939-A706BFDB437DQ48451343-1715E451-7B9F-4E01-9166-AA3D06310F72Q49843356-5291BE90-E28B-4C84-8F46-F8C1F6669F1AQ51287697-ED0BA455-4AFC-4747-93CB-E0B8C1719EAA
P2860
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@ast
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@en
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@nl
type
label
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@ast
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@en
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@nl
prefLabel
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@ast
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@en
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@nl
P2860
P356
P1476
Clinical pharmacology of rasag ...... treatment of Parkinson disease
@en
P2093
David M Swope
Jack J Chen
P2860
P304
P356
10.1177/0091270005277935
P407
P577
2005-08-01T00:00:00Z